ASH 2023 | Analyzing circulating tumor DNA to determine remission in patients with lymphoma
Mark Roschewski
• 8 Dec 2023
Mark Roschewski, MD, National Cancer Institute, Bethesda, MD, discusses the analysis of circulating tumor DNA (ctDNA) in blood samples as an alternative to PET/CT scans for determining remission in patients with lymphoma. A comparison of the two revealed that circulating tumor DNA is a more accurate predictor of active lymphoma, with a high negative predictive value. In contrast, PET/CT scans are often positive without disease progression. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
